Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

NCT03978832 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: PERSERIS
DRUG: Risperidone

Sponsor

Indivior Inc.